RegeneRx takes away cash from Lee's Asian thymosin deal but more needed
This article was originally published in Scrip
The Hong Kong-based firm Lee's Pharmaceutical has acquired rights in China and other selected Asian markets to RegeneRx Biopharmaceuticals' portfolio of thymosin beta-4 (TB-4) therapeutics, throwing a temporary lifeline to the troubled US firm.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.